Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.56 |
| ▸ | THRB | P10828 | 12/20 | 0.56 |
| ▸ | GSR | P00390 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3324195 | 0.98 | THRA (0.54) | THRATHRBGSREGFR | |
| SCHEMBL12123731 | 0.86 | THRA (0.58) | THRATHRBGSREGFR | |
| SCHEMBL12949980 | 0.82 | HSD17B3 (0.50) | — | |
| SCHEMBL9423799 | 0.82 | EGFR (0.50) | THRATHRBGSREGFR | |
| SCHEMBL6812061 | 0.81 | HSD17B3 (0.58) | — | |
| SCHEMBL8402206 | 0.81 | HSD17B3 (0.51) | THRATHRB | |
| SCHEMBL9509983 | 0.80 | GSR (0.72) | THRATHRBGSREGFR | |
| SCHEMBL17551934 | 0.80 | THRA (0.61) | THRATHRBEGFR | |
| SCHEMBL8214726 | 0.79 | KMT2A (0.59) | — | |
| SCHEMBL29269279 | 0.79 | ESR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | THRA 1897/4885THRB 1083/4885GSR 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.